That’s more like it! ‘Compelling 85% success rates from Remplir™...

That’s more like it!
‘Compelling 85% success rates from Remplir™ nerve repair study
published in peer-reviewed clinical journal
• Peripheral nerve repair clinical study showing consistent return of muscle function to paralysed upper
limbs, following nerve repair with Remplir™, now published in peer-reviewed Journal of Reconstructive
Microsurgery Open.
• Results showed 85% (23 of 27) of nerve repairs with Remplir, at 24 months post treatment, resulted in
functional recovery of muscles controlled by the repaired nerve.
• Compelling outcomes confirm Othocell’s nerve repair product, Remplir, as the ideal medical device for
the connecting of severed nerves, protecting damaged nerves or capping amputated nerves.
• Top-line results from US FDA Remplir nerve repair study are expected in Q3 CY24, and Orthocell remains
on schedule to submit its US 510(K) market authorisation application in Q4 CY24 with progression into
sales soon thereafter.
• Publication will likely significantly raise the profile of Remplir with potential partners, practitioners and
patients where the Company has the potential to become the leading device in the US in an addressable
market estimated to be worth more than US$1.1 billion per annum.’